Rezolute, Inc.

Rezolute, Inc. is a late-stage rare disease company focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody. Ersodetug is currently in Phase 3 clinical trials for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia associated with tumor hyperinsulinism. The company was founded in 2010 and is headquartered in Redwood City, California. It was formerly known as AntriaBio, Inc. before rebranding in December 2017.

Rezolute, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol RZLT. The company trades in U.S. dollars (USD), which is the currency of its home country, the United States. As a Nasdaq-listed company, it is subject to the reporting and governance standards of that exchange.

Rezolute operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing therapies for rare diseases, particularly those involving hypoglycemia caused by hyperinsulinism. Its work involves monoclonal antibody technology, with its lead candidate ersodetug targeting congenital hyperinsulinism and tumor hyperinsulinism. The company's efforts are centered on late-stage clinical development, aiming to bring treatments to patients with significant unmet medical needs.

Rezolute is headquartered in Redwood City, California, United States. The company primarily serves the U.S. market, as indicated by its focus on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its clinical programs are directed at addressing rare diseases within the country, though its research and development efforts may have broader implications. The company's geographic focus is domestic, with its operations and clinical trials centered in the U.S.

Rezolute's lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody. It is being developed for the treatment of hypoglycemia caused by hyperinsulinism. Specifically, ersodetug is in Phase 3 clinical trials for congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, and for hypoglycemia associated with tumor hyperinsulinism. Congenital hyperinsulinism leads to persistently low blood sugar in infants and children, while tumor hyperinsulinism involves insulin-secreting tumors. Ersodetug aims to address these conditions by targeting the underlying mechanism of excess insulin.